Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Alvotech and Johnson & Johnson strike settlement agreements for AVT04 biosimilar.

flag Alvotech, a biotech company specializing in biosimilar medicines, announced it has reached settlement agreements with Johnson & Johnson to launch its biosimilar AVT04, a version of Stelara® (ustekinumab), in Japan, Canada, and the European Economic Area (EEA). flag The company expects to enter the Canadian market in Q1 2024 and Japan in May 2024, pending local approval. flag Entry to the European markets is anticipated after the expiration of the European Supplementary Protection Certificate for Stelara in late July 2024. flag Alvotech has partnered with various commercial entities for the launch of AVT04 in these regions, including Fuji Pharma Co. Ltd., JAMP Pharma Group, and STADA Arzneimittel AG.

14 months ago
6 Articles